Today marks a new chapter for WellTheory — and for the millions of Americans living with autoimmune disease.

We’re proud to announce our $14M Series A funding led by General Catalyst, with participation from 7wire Ventures, Ingeborg Investments, Accel, Box Group, and Up2 Opportunity Fund.

This milestone means so much more than funding. It’s proof that the world is starting to pay attention to an epidemic that’s been ignored for far too long.

The Growing Autoimmune Crisis

Autoimmune disease affects over 50 million Americans, 80% of whom are women. Yet for decades, it’s been misunderstood, underdiagnosed, and overlooked.

These conditions are rising faster than any other disease category, doubling in prevalence in just 30 years.

The costs are staggering. Autoimmune disease now represents a $150B+ annual market, a figure that continues to climb as new immunology drugs come to market. These conditions account for 50% of all specialty drug spend, which has risen 459% over the past decade. 

Employers and health plans feel this burden acutely, but autoimmune diseases are often invisible in claims data — scattered across specialties, never tied back to the same root cause.

Behind those numbers are real people. People who have spent years searching for answers, only to be told their labs look “normal” or that their symptoms are “all in their head.”

From Personal Stories to a Shared Mission

I know that story because I lived it. 

At 25, I was bedridden and desperate for answers. I spent months cycling through specialists and tests, hoping someone would finally connect the dots.

When I was eventually diagnosed with an autoimmune condition, I realized just how broken the system was and how many others were being left behind. Along the way, I connected with my co-founders, Claire and Wallace, whose lives had also been touched by autoimmune disease.

Together, we decided to build the solution we all wished had existed at the start of our journeys — care that’s personalized, proactive, and rooted in compassion.

When we launched WellTheory, our goal was simple but ambitious: to reimagine autoimmune care from the ground up with a model that looks at the whole person, not just the diagnosis.

What started as a small, passionate community has grown into something much larger. Today, we’re seeing thousands of members reduce symptoms, regain energy, and rebuild their lives after years of being dismissed.

Employers and health plans are also recognizing what patients have known all along: autoimmune conditions can’t be treated in silos. They’re now turning to WellTheory to address autoimmune conditions at scale — not as isolated diseases, but as systemic issues affecting every aspect of well-being and productivity.

Built & Backed by Women: Defying the Odds

As a woman living with autoimmune disease, I’ve spent years navigating systems that weren’t built for patients like me — or founders like me, either.

Less than 2% of venture capital goes to women. Only 17% of VC decision-makers are women. And women’s health continues to be chronically underfunded.

That’s why this round feels especially meaningful and why I couldn't be prouder that our cap table reflects the patients we serve. 

When I met Candace and Holly from General Catalyst, I knew I’d found partners who truly understood. Both had personal connections to autoimmune disease — they’d seen the toll it takes on people they love. 

They believed in this mission not just as investors, but as women who have seen the system fail people they love and who want to change it.

I’m also grateful to have Alyssa and Tiffany from 7wire Ventures and Anna and Mira from Ingeborg Investments joining this mission — women who share our conviction that health equity and access go hand in hand.

Together, we’re showing what happens when women build, back, and lead in healthcare, and it feels like we’re building the system we’ve always deserved to see.

What’s Ahead

In just the last year, WellTheory has grown more than 10x in membership and partnered with visionary employers and payors like Fortune Brands, Dayforce, and Sentara Health Plans.

We’ve built proprietary AI tools — Care Hub and Care Scribe — to help our care teams personalize support and improve health outcomes at scale.

This funding allows us to go even further to:

• Deepen partnerships with employers and health plans
• Expand our care programs to reach more people and conditions
• Accelerate AI development to make our care even more personalized and accessible

We’re investing in technology, clinical research, and enterprise expansion to bring this model to millions — because addressing autoimmune disease isn’t just about managing symptoms; it’s about redefining what care can look like.

P.S. We’re growing fast and hiring across teams. If you feel called to our mission and driven by grit, resilience, and a belief that change happens when people refuse to accept the status quo — we’d love to meet you.